Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AbCellera Biologics Inc. or Bruker Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AbCellera Biologics Inc. and Bruker Corporation compare based on key financial metrics to determine which better meets your investment needs.

About AbCellera Biologics Inc. and Bruker Corporation

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Latest Life Sciences Tools & Services and AbCellera Biologics Inc., Bruker Corporation Stock News

As of July 31, 2026, AbCellera Biologics Inc. had a $1.7 billion market capitalization, compared to the Life Sciences Tools & Services median of $1.8 million. AbCellera Biologics Inc.’s stock is up 67% in 2026, up 7.5% in the previous five trading days and up 24.95% in the past year.

Currently, AbCellera Biologics Inc. does not have a price-earnings ratio. AbCellera Biologics Inc.’s trailing 12-month revenue is $79.2 million with a -181.7% net profit margin. Year-over-year quarterly sales growth most recently was 97.6%. Analysts expect adjusted earnings to reach $-0.650 per share for the current fiscal year. AbCellera Biologics Inc. does not currently pay a dividend.

As of July 31, 2026, Bruker Corporation had a $9.6 billion market cap, putting it in the 77th percentile of all stocks. Bruker Corporation’s stock is up 33.4% in 2026, up 4% in the previous five trading days and up 53.66% in the past year.

Currently, Bruker Corporation does not have a price-earnings ratio. Bruker Corporation’s trailing 12-month revenue is $3.5 billion with a -0.3% net profit margin. Year-over-year quarterly sales growth most recently was 2.7%. Analysts expect adjusted earnings to reach $2.120 per share for the current fiscal year. Bruker Corporation currently has a 0.3% dividend yield.

How We Compare AbCellera Biologics Inc. and Bruker Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AbCellera Biologics Inc. and Bruker Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AbCellera Biologics Inc. and Bruker Corporation Growth Grades

Company	Ticker	Growth
AbCellera Biologics Inc.	ABCL	F
Bruker Corporation	BRKR	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

AbCellera Biologics Inc. has a Growth Score of 10, which is Very Weak. Bruker Corporation has a Growth Score of 89, which is Very Strong.

The Growth Grade Winner: Bruker Corporation

As you can clearly see from the Growth Grade breakdown above, Bruker Corporation has a more attractive growth grade than AbCellera Biologics Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Bruker Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbCellera Biologics Inc. and Bruker Corporation’s Quality Grades

Company	Ticker	Quality
AbCellera Biologics Inc.	ABCL	D
Bruker Corporation	BRKR	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

AbCellera Biologics Inc. has a Quality Score of 21, which is Weak. Bruker Corporation has a Quality Score of 64, which is Strong.

The Quality Grade Winner: Bruker Corporation

As you can clearly see from the Quality Grade breakdown above, Bruker Corporation has a better overall quality grade than AbCellera Biologics Inc.. For investors who are looking for companies with higher quality than others in the same industry, Bruker Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbCellera Biologics Inc. and Bruker Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
AbCellera Biologics Inc.	ABCL	B
Bruker Corporation	BRKR	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

AbCellera Biologics Inc. has a Earnings Estimate Score of 67, which is Positive. Bruker Corporation has a Earnings Estimate Score of 53, which is Neutral.

The Earnings Estimate Revisions Grade Winner: AbCellera Biologics Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, AbCellera Biologics Inc. has a better Earnings Estimate Revisions Grade than Bruker Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, AbCellera Biologics Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other AbCellera Biologics Inc. and Bruker Corporation Grades

In addition to Estimate Revisions, Quality and Growth, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AbCellera Biologics Inc. and Bruker Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AbCellera Biologics Inc. or Bruker Corporation Stock?

Overall, AbCellera Biologics Inc. stock has a Growth Score of 10, Estimate Revisions Score of 67 and Quality Score of 21.

Bruker Corporation stock has a Growth Score of 89, Estimate Revisions Score of 53 and Quality Score of 64.

Comparing AbCellera Biologics Inc. and Bruker Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.